Intestine Cancer Therapeutics Market Report 2026

Intestine Cancer Therapeutics Market Overview

• Intestine Cancer Therapeutics market size has reached to $15.12 billion in 2025 • Expected to grow to $22.96 billion in 2030 at a compound annual growth rate (CAGR) of 8.9% • Growth Driver: Rising Prevalence Of Hereditary Colorectal Cancer Syndromes Fuels Growth In Intestine Cancer Therapeutics Market • Market Trend: Increasing Focus On Product Approvals To Drive The Revenues • Asia-Pacific was the largest region in 2025 and North America is the fastest growing region.

What Is Covered Under Intestine Cancer Therapeutics Market?

Intestine cancer therapeutics refer to the various treatment options available for small intestine and colorectal cancer that affect the digestive system. These treatments aim to remove or manage cancerous cells and improve patient outcomes. The specific treatment plan will depend on the stage of the cancer, the patient's overall health, and other factors. The main types of treatments for intestine cancer therapeutics are immunotherapy, chemotherapy, and others. Immunotherapy is a type of cancer treatment that utilizes the body's immune system to fight cancer cells. They are distributed through various distribution channels including hospital pharmacies, online pharmacies, and retail pharmacies, which are utilized by hospitals, homecare, specialty centers, and others.

What Is The Intestine Cancer Therapeutics Market Growth Forecast?

The intestine cancer therapeutics market size is expected to see strong growth in the next few years. It will grow to $22.96 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to growing adoption of immunotherapy treatments, increasing investment in oncology research, rising demand for targeted cancer therapies, expansion of personalized cancer treatment approaches, improved survival outcomes driving long-term treatment demand. Major trends in the forecast period include increasing adoption of combination cancer therapies, growing focus on early-stage cancer treatment, rising use of multimodal treatment approaches, expansion of specialized oncology treatment centers, improved patient access to advanced cancer care.

What Is The Driver Of The Intestine Cancer Therapeutics Market?

The increasing prevalence of hereditary colorectal cancer syndromes is expected to propel the growth of the intestine cancer therapeutics market going forward. Hereditary colorectal cancer syndromes are a group of genetic conditions that increase an individual's risk of developing colorectal cancer (colon or rectum cancer). Hereditary colorectal cancer syndromes play a significant role in intestinal cancer therapeutics, providing information associated with specific genetic mutations that substantially increase the risk of developing colorectal cancer. For instance, in July 2023, according to the World Health Organization, a Switzerland-based intergovernmental organization, by 2040, the prevalence of hereditary colorectal cancer is projected to increase significantly, with an estimated 3.2 million new cases and 1.6 million deaths annually. This represents a 63% increase in new cases and a 73% increase in fatalities compared to the current rates. Therefore, the increasing prevalence of hereditary colorectal cancer syndromes is driving the growth of the intestine cancer therapeutics industry.

Key Players In The Global Intestine Cancer Therapeutics Market

Major companies operating in the intestine cancer therapeutics market are Pfizer Inc., Johnson & Johnson Private Limited, Roche Holding AG, AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck KGaA, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Ltd., Ipsen Pharma, Hikma Pharmaceuticals plc, Amneal Pharmaceuticals LLC, Cipla Inc., Aurobindo Pharma Limited, Lupin Limited

Global Intestine Cancer Therapeutics Market Trends and Insights

Major companies operating in the intestine cancer therapeutics market are developing innovative products such as Lonsurf and getting approvals to meet larger customer bases, more sales, and increased revenue. LONSURF is a combination of two drugs, trifluridine and tipiracil, for treating adult patients with metastatic colorectal cancer. For instance, in August 2023, Taiho Oncology Inc., a US-based pharmaceutical company, received approval for Lonsurf from the US Food and Drug Administration. Lonsurf is available as a single oral tablet. Trifluridine works by stopping the growth of cancer cells, while tipiracil helps trifluridine to work longer by preventing it from being broken down by the body. The approval of Lonsurf provides patients with metastatic colorectal cancer and other eligible cancers access to a new treatment option that may improve outcomes and quality of life.

What Are Latest Mergers And Acquisitions In The Intestine Cancer Therapeutics Market?

In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for $43 billion. Through this acquisition, Pfizer aims to strengthen its oncology therapeutics portfolio by integrating Seagen’s innovative antibody–drug conjugate (ADC) technologies, which are being evaluated across various solid tumors, including HER2-positive metastatic colorectal cancer. Seagen Inc. is a US-based biotechnology company specializing in targeted cancer medicines, particularly advanced ADC platforms used in developing novel treatments for colorectal and other solid tumors.

What Defines the Intestine Cancer Therapeutics Market?

The intestine cancer therapeutics market includes revenues earned by entities by provide services such as colonoscopies and fecal occult blood tests, clinical trials, supportive care, genetic testing and counseling, and psychological support. The market value includes the value of related goods sold by the service provider or included within the service offering. The intestine cancer therapeutics market also includes sales of Alymsys, Avastin (bevacizumab), bevacizumab, Camptosar (irinotecan hydrochloride), capecitabine, cetuximab, angiogenesis inhibitors, multikinase inhibitors, epigenetic agents, and supportive care products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Intestine Cancer Therapeutics Market Report 2026?

The intestine cancer therapeutics market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the intestine cancer therapeutics industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.